

[Pretomanid](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

ATC codes: [J04AK08](#)

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

INN

Pretomanid

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Solid > tablet:** 200 mg

EML status history

First added in 2023 ([TRS 1049](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

Read more [about patents](#).

Wikipedia

[Pretomanid](#)

DrugBank

[Pretomanid](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.